Response-based chemotherapy and involved field radiation for intermediate stage Hodgkin disease. A GISL/NHLSG trial

被引：0
|
作者：
Iannitto, E. [1 ]
Minardi, V. [1 ]
Gobbi, P. G. [2 ]
Luminari, S. [3 ]
Calvaruso, G. [1 ]
Stelitano, C. [4 ]
Baldini, L. [5 ]
Merli [6 ]
Petrini, M. [7 ]
Marcheselli, L. [3 ]
Mammi, C. [3 ]
De Cantis, S. [1 ]
Abbadessa, V [1 ]
Federico, M. [3 ]
机构：
[1] Univ Palermo, I-90133 Palermo, Italy
[2] Univ Pavia, I-27100 Pavia, Italy
[3] Univ Modena & Reggio Emilia, Dept Hematol & Oncol, Modena, Italy
[4] Osped Bianchi Melacrino Morelli, Reggio Di Calabria, Italy
[5] Univ Milan, Dipartimento Ematol, I-20122 Milan, Italy
[6] Osped SM Nuova, Reggio Emilia, Italy
[7] Univ Pisa, I-56100 Pisa, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1 / 1
页数：1
相关论文
共 50 条
  • [31] A novel approach to the treatment of early stage Hodgkin's disease with mitoxantrone-based regimen followed by involved field radiotherapy.
    O'Brien, TM
    Anupama, R
    Venugopal, P
    Kaplan, EH
    Gupta-Burt, S
    Foster, GS
    Gregory, SA
    BLOOD, 1999, 94 (10) : 265B - 265B
  • [32] Radiation therapy following complete clinical response after "ABVD" chemotherapy in Hodgkin's disease: is there a need - prospective trial from a single institution
    Laskar, S
    Muckaden, MA
    Saikia, TK
    Pai, SK
    Malde, R
    Ingle, P
    Sanghvi, V
    Bhalla, V
    Homkar, G
    Dedhia, R
    Shukla, A
    Dinshaw, KA
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 131 - 131
  • [33] Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma
    Moser, Elizabeth C.
    Kluin-Nelemans, Hanneke C.
    Carde, Patrice
    Meerwaldt, Jacobus H.
    Tirelli, Umberto
    Aleman, Berthe M. P.
    Baars, Joke
    Thomas, Jose
    Van Glabbeke, Martine
    Noordijk, Evert M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (04): : 1168 - 1177
  • [34] Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy
    Nachman, JB
    Sposto, R
    Herzog, P
    Gilchrist, GS
    Wolden, SL
    Thomson, J
    Kadin, ME
    Pattengale, P
    Davis, PC
    Hutchinson, RJ
    White, K
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) : 3765 - 3771
  • [35] Results of the 4th interim analysis of the HID 11 trial of the GHSG for intermediate stage Hodgkin's lymphoma:: 30 Gy versus 20 Gy involved field radiotherapy
    Eich, HT
    Müller, RP
    Hansemann, K
    Engert, A
    Pfistner, B
    STRAHLENTHERAPIE UND ONKOLOGIE, 2005, 181 : 49 - 49
  • [36] Cyclophosphamide-based, seven-drug hybrid and low-dose involved field radiation for the treatment of childhood and adolescent Hodgkin disease
    Hamilton, VM
    Norris, C
    Bunin, N
    Goldwein, JW
    Bunin, GR
    Lange, B
    Meadows, AT
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2001, 23 (02) : 84 - 88
  • [37] Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease
    Donaldson, Sarah S.
    Link, Michael P.
    Weinstein, Howard J.
    Rai, Shesh N.
    Brain, Sam
    Billett, Amy L.
    Hurwitz, Craig A.
    Krasin, Matthew
    Kun, Larry E.
    Marcus, Karen C.
    Tarbell, Nancy J.
    Young, Jeffrey A.
    Hudson, Melissa M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (03) : 332 - 337
  • [38] Cyclophosphamide-based, seven-drug hybrid and low-dose involved field radiation for the treatment of childhood and adolescent Hodgkin disease
    Nitschke, R
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2001, 23 (06) : 368 - 369
  • [39] A comparison of traditional vs. response-based involved-field radiotherapy on clinical target volume and organs at risk for pediatric rapid early responders with high-risk Hodgkin lymphoma
    Wilson, Joella E.
    South, Michael
    Teh, Bin S.
    Butler, E. Brian
    Paulino, Arnold C.
    JOURNAL OF RADIATION ONCOLOGY, 2014, 3 (01) : 99 - 104
  • [40] The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease
    Wendland, MMM
    Asch, JD
    Pulsipher, MA
    Thomson, JW
    Shrieve, DC
    Gaffney, DK
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (02): : 189 - 195
12345